Optimal Treatment of Non-Muscle Invasive Urothelial Carcinoma Including Perioperative Management Revisited-Reference-Cited by-同舟云学术

Optimal Treatment of Non-Muscle Invasive Urothelial Carcinoma Including Perioperative Management Revisited

Published:2014-09-19 Issue:11 Volume:15 Page:
ISSN:1527-2737
Container-title:Current Urology Reports
language:en
Short-container-title:Curr Urol Rep

Author:

Pagano Matthew J.,Badalato Gina,McKiernan James M.

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11934-014-0450-1.pdf

Reference79 articles.

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society. 2013.

2. American Urological Association: guideline for the management of nonmuscle invasive bladder cancer (stages T1, T1, and TIS): 2007 Update. Reviewed and validity confirmed 2010. 2007.

3. Swinn MJ, Walker MM, Harbin LJ, Adshead JM, Witherow RO, Vale JA, et al. Biopsy of the red patch at cystoscopy: is it worthwhile? Eur Urol. 2004;45(4):471–4. doi: 10.1016/j.eururo.2003.11.019 . discussion 4.

4. May F, Treiber U, Hartung R, Schwaibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol. 2003;44(1):47–50.

5. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol. 1999;35(4):267–71.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Risk NMIBC and TURBT;Management of Non-Muscle Invasive Bladder Cancer;2019-10-24

2. Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis;BioMed Research International;2019-08-25